Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 4 clients • 7 examiners • 7 art units • 0 of 8 (0%) have an AI response strategy ready
EpiMED LLC has 7 pending office actions in Biotechnology & Pharmaceuticals and 157 career applications. The active workload and application history identify a focused life-sciences prosecution practice.
The resolved allowance rate is 57.14%, with an average of 3.5 office actions per allowance. The results show allowance in a smaller share of resolved matters and a measurable examination burden for matters reaching allowance.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (12%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 2 | 56.9% | +20.0% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.6% | +62.3% |
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| SAOUD, CHRISTINE J | 1 | 57.9% | +37.5% |
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.9% | +41.8% |
| EDWARDS, JESSICA FAYE | 1 | 38.3% | +47.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773240 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | DRISCOLL, MAUREEN VARINA | 259d overdue |
| 17772464 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | EDWARDS, JESSICA FAYE | 14d |
| 18039272 | STABLE SEMI-SOLID CHEWABLE GEL COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | HOERNER, PAUL ELLSWORTH | — |
| 18030754 | Camptothecin Derivative And Ligand-drug Conjugate Thereof | ALDARONDO, DASIA ALI | — |
| 16760466 | BISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | AEDER, SEAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773240 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | DRISCOLL, MAUREEN VARINA | 259d overdue |
| 17772464 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | EDWARDS, JESSICA FAYE | 14d |
| 17909360 | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | KELLY, ROBERT M | 33d |
| 18693507 | METHODS OF TREATING CANCER AND THE PHARMACEUTICAL COMPOSITIONS THEREOF | AEDER, SEAN E | — |
| 18039272 | STABLE SEMI-SOLID CHEWABLE GEL COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | HOERNER, PAUL ELLSWORTH | — |
| 18029043 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | SAOUD, CHRISTINE J | — |
| 16760466 | BISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | AEDER, SEAN E | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Baili-Bio (Chengdu) Pharmaceutical | 5 |
| Systimmune, Inc. | 1 |
| Seattle Gummy Company | 1 |
| Sichuan Baili Pharmaceutical Co. Ltd. | 1 |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1611 | 1 |
| 1625 | 1 |
| 1645 | 1 |
| 1638 | 1 |
| 1644 | 1 |
| 1657 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18693507 | METHODS OF TREATING CANCER AND THE PHARMACEUTICAL COMPOSITIONS THEREOF | Systimmune, Inc. | AEDER, SEAN E | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18039272 | STABLE SEMI-SOLID CHEWABLE GEL COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | Seattle Gummy Company | HOERNER, PAUL ELLSWORTH | 1611 | §103§112 | Non-Final OA | — | Pending | May 29, 2023 |
| 18030754 | Camptothecin Derivative And Ligand-drug Conjugate Thereof | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | ALDARONDO, DASIA ALI | 1625 | §103 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18029043 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | SAOUD, CHRISTINE J | 1645 | §102§103§112DP | Non-Final OA | — | Pending | Mar 28, 2023 |
| 17909360 | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | KELLY, ROBERT M | 1638 | §112 | Non-Final OA | 33d | Pending | Sep 03, 2022 |
| 17773240 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | DRISCOLL, MAUREEN VARINA | 1644 | §103§112Other | Non-Final OA | 259d overdue | Pending | Apr 29, 2022 |
| 17772464 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. | EDWARDS, JESSICA FAYE | 1657 | §102§103§112Other | Final Rejection | 14d | Pending | Apr 27, 2022 |
| 16760466 | BISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | Sichuan Baili Pharmaceutical Co. Ltd. | AEDER, SEAN E | 1642 | §103§112 | Non-Final OA | — | Pending | Apr 30, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial57.1% of resolved applications prosecuted by Epimed LLC were allowed, across 157 applications in USPTO records.
3.50 office actions per allowed application on average.
8 pending office actions as of October 2026, for 4 clients, before 7 examiners in 7 art units.
